



DT05 Rec'd PCT/PTO

10 SEP 2002  
PATENT

2630

Case D No. WWELL63.001APC  
Date: September 4, 2002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Grassi, et al.  
Appl. No. : 10/089,127  
Filed : March 22, 2002  
For : RIBOZYMES FOR  
PREVENTION OF  
RESTENOSIS  
Examiner : Unknown  
Group Art Unit : Unknown

) I hereby certify that this correspondence and all marked  
) attachments are being deposited with the United States  
) Postal Service as first class mail in an envelope  
) addressed to: United States Patent and Trademark  
) Office, P.O. Box 2327, Arlington, VA 22202, on

September 4, 2002

(Date)

Mark R. Benedict, Reg. No. 44,531

## TRANSMITTAL LETTER


United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with eight (8) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

  
Mark R. Benedict  
Registration No. 44,531  
Attorney of Record



001APC

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Grassi, et al. ) Group Art Unit: Unknown  
App. No. : 10/089,127 )  
Filed : March 22, 2002 )  
For : RIBOZYMES FOR )  
PREVENTION OF )  
RESTENOSIS )  
Examiner : Unknown )

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON &amp; BEAR, LLP


Dated: 9/4/02By: Mark R. Benedict

Mark R. Benedict  
Registration No. 44,531  
Attorney of Record  
2040 Main Street  
Fourteenth Floor  
Irvine, CA 92614  
(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
WWELL63.001APCAPPLICATION NO.  
10/089,127INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Grassi, et al.FILING DATE  
March 22, 2002GROUP  
Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	1. Barr, et al. (1993) Gene Transfer into Cardiac and Skeletal Myocytes in vivo. J. Cell Biochem. 17D:192.
	2. Geng, Y., et al. (1996) Regulation of cyclin E transcription by E2Fs and Retinoblastoma Protein. Oncogene 12:1173-1180.
	3. Grassi, G., et al. (1998) Growth Inhibition of Smooth Muscle Cells From Human Coronary Plaque Tissues by Hammerhead Ribozymes. Pathol. Res. Pract. 194(4):267 (Abstract 214).
	4. Helin, K., et al. (1992) A cDNA Encoding a pRB-Binding Protein with Properties of the Transcription Factor E2F. Cell 70:337-350.
	5. Koff, A., et al. (1991) Human Cyclin E, a New Cyclin That Interacts with Two Members of the CDC2 Gene Family. Cell 66:1217-1228.
	6. Lapham, et al. (1996) RNase H cleavage for processing of in vitro transcribed RNA for NMR studies and RNA ligation. RNA 2:289.
	7. Symons, R. H. (1992) Small Catalytic RNAs. Annu. Rev. Biochem. 61:641-671.
	8. Zarinkar, et al. (1996) The kinetic folding pathway of the <i>Tetrahymena</i> ribozyme reveals possible similarities between RNA and protein folding. Nature Struct. Biol. 3:432.

O:\DOCS\MXG\MXG-1443.DOC:vb 082202

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	